Tata Elxsi Limited has signed a Memorandum of Understanding (MoU) with Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST) to collaborate on the development of next-generation healthcare solutions. The agreement, signed on July 27, 2026, in Thiruvananthapuram, establishes a strategic partnership aimed at accelerating medical technology development by combining SCTIMST's clinical research strengths with Tata Elxsi's advanced engineering and design capabilities. This collaboration creates a unified ecosystem for MedTech companies to develop, validate, and scale new products more efficiently, addressing evolving healthcare needs in India and global markets.

The MoU was signed in the presence of senior leaders from both organizations, including Dr. Sanjay Behari, Director of SCTIMST, and Manoj Raghavan, CEO & Managing Director of Tata Elxsi. The disclosure was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and published on the company's website. The partnership leverages SCTIMST's status as an Institution of National Importance under the Department of Science and Technology (DST), Government of India, bringing together its Super Specialty Hospital, Biomedical Technology Wing, and Achutha Menon Centre for Health Science Studies.

Strategic Collaboration Areas

The partnership focuses on integrating complementary strengths across healthcare, technology, and product development. SCTIMST contributes expertise in cardiovascular sciences, neurosciences, biotechnology, and clinical sciences, while Tata Elxsi provides capabilities in product engineering, design, artificial intelligence, and digital technologies. The collaboration targets key areas including diagnostics, medical imaging, digital health, biomedical engineering, and medical devices. Unlike traditional industry-academia engagements, this model creates an extended innovation environment that includes clinicians, specialist researchers, advanced laboratories, and prototyping infrastructure within a single collaborative ecosystem.

Sreevatsa Sahasranaman, Senior Vice President and Head of Healthcare and Life Sciences at Tata Elxsi, stated that healthcare innovation increasingly depends on closer collaboration between clinicians, scientists, and engineering teams. He noted that SCTIMST adds significant depth to the collaboration through its strong research and innovation capabilities, helping to bring India-led innovation to global healthcare markets. The MoU establishes a framework for joint research, academic engagement, technology development initiatives, and intellectual property creation through project-specific collaborations.

Partnership Significance

The partnership represents a structural shift in how Tata Elxsi approaches healthcare innovation, moving beyond service delivery to embedded R&D collaboration. By integrating directly with SCTIMST's clinical and research infrastructure, Tata Elxsi reduces the time-to-market for new medical technologies. This model allows MedTech customers to access biocompatibility, toxicology, and validation services within the same ecosystem where product engineering occurs. The focus on high-potential opportunities suggests a targeted approach to scaling specific therapeutic areas, potentially improving the efficiency of capital deployment in healthcare projects.

Tata Elxsi received an order from the Commissioner of Income Tax (Appeals) regarding a penalty of Rs 67,29,774, with the company stating that the development is not expected to have a material financial impact. The order, passed under Section 250 of the Income Tax Act, 1961, was received on July 20, 2026, and relates to an appeal against a penalty levied under Section 271(1) of the Act.

The disclosure was made to the exchanges in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that the total order amount stands at Rs 67,29,774.

Details of the Order

The filing provided specific particulars regarding the communication from the tax authority. The order addresses the penalty levied on the company, which Tata Elxsi had previously appealed.

Company Response

Tata Elxsi stated that it is currently reviewing the order and will take appropriate action as required. The company noted that, based on a preliminary assessment, the order is not expected to have any material financial impact on its operations.